30/12/2020 |
Change of Director’s Interest Notice – Gordon |
30/12/2020 |
Change of Director’s Interest Notice – Halasz |
30/12/2020 |
Change of Director’s Interest Notice – King |
24/12/2020 |
Confirming Changes to the Cellmid Board |
23/12/2020 |
Newsletter |
16/12/2020 |
Appendix 2A |
16/12/2020 |
Change of Director’s Interest Notice – Eck |
14/12/2020 |
Cellmid Signs 10 Year Chinese Distribution Agreement |
02/12/2020 |
Final Director’s Interest Notice – Walton |
02/12/2020 |
Initial Director’s Interest Notice – Eck-Thompson |
30/11/2020 |
AGM Presentation to Shareholders |
30/11/2020 |
Annual General Meeting – Change of Agenda |
30/11/2020 |
Results of Meeting |
23/11/2020 |
Annual General Meeting Update |
12/11/2020 |
Growth Strategy Presentation |
05/11/2020 |
Release of Shares from Voluntary Escrow |
01/11/2020 |
Letter to Shareholders – Notice of Annual General Meeting |
01/11/2020 |
Notice of Annual General Meeting/Proxy Form |
21/10/2020 |
Appendix 4C and Quarterly Activity Report |
21/10/2020 |
Board Renewal To Align With Consumer Health Growth Strategy |
14/10/2020 |
2020 Annual General Meeting |
07/10/2020 |
Section 249D Notice |
15/09/2020 |
2020 Annual Report to shareholders |
15/09/2020 |
Appendix 4G and Corporate Governance Statement |
10/09/2020 |
CDY Engages Advisers to Facilitate Divestment from Lyramid |
27/08/2020 |
Appendix 4E and FY20 Financial Report |
27/08/2020 |
FY20 Financial Results |
27/08/2020 |
FY20 Results Presentation |
28/07/2020 |
Cellmid signed exclusive agreement with premium salon distributor in the USA |
22/07/2020 |
Cellmid Appendix 4C-Q4 FY2020 Business Activity |
09/07/2020 |
ASX Aware query |
09/07/2020 |
Cellmid signs exclusive agreement for SARS-CoV-2 laboratory tests |
07/07/2020 |
Market release – Pause in trading |
05/07/2020 |
Extension of Wondfo Sars-coV-2 rapid test distribution agreement |
23/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
18/06/2020 |
Appendix 2A – Application for quotation of +securities |
18/06/2020 |
Appendix 3G – Notification of issue, conversion or payment up of equity +securities |
18/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
18/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
18/06/2020 |
Form 604 – Notice of change of interests of substantial holder |
16/06/2020 |
Cellmid reports on strong QVC sales event |
15/06/2020 |
Cellmid reports on results of the Doherty Institute testing |
04/06/2020 |
Cellmid signs introducer agreement to broaden product offering |
01/06/2020 |
Cellmid appoints Dr Dominic Burg as Chief Operating Officer |
22/05/2020 |
General Meeting – May 2020 |
22/05/2020 |
Results of May 2020 General Meeting |
15/05/2020 |
Company update and extension of voluntary suspension |
14/05/2020 |
Amendment to notice of general meeting |
11/05/2020 |
Cellmid Limited (ASX: CDY) – Suspension from Official Quotation |
07/05/2020 |
Cellmid Limited (ASX: CDY) – Trading Halt |
07/05/2020 |
Pause in Trading |
04/05/2020 |
Appendix 2A – Application for quotation of +securities |
04/05/2020 |
Cellmid share purchase plan completed |
30/04/2020 |
Cellmid’s Alopecia patent allowed in Australia and Japan |
27/04/2020 |
Cellmid Appendix 4C – Q3 FY2020 business activity |
22/04/2020 |
Independent test results for the Wondfo Sars-Cov2 Test |
22/04/2020 |
Notice of May 2020 General Meeting |
16/04/2020 |
Share Purchase Plan |
14/04/2020 |
Appendix 2A – Application for quotation of +securities |
14/04/2020 |
Cellmid’s shipment of Sars-Cov2 test received |
14/04/2020 |
Market Release – Pause in Trading |
08/04/2020 |
An offer of +securities under a +securities purchase plan |
07/04/2020 |
Cellmid Limited (ASX: CDY) – Reinstatement to Official Quotation |
07/04/2020 |
Cellmid share placement raises $6 million |
07/04/2020 |
Total number of +securities proposed to be issued for a placement or other type of issue |
06/04/2020 |
Cellmid Limited (ASX: CDY) – Suspension from Official Quotation |
01/04/2020 |
Cellmid Limited (ASX: CDY) – Trading Halt |
28/03/2020 |
Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement |
28/03/2020 |
Market Update on COVID-19 |
28/03/2020 |
Reinstatement to Official Quotation |
06/03/2020 |
New Distribution channels to drive revenue growth from 2H FY2020 |
04/03/2020 |
Appendix 3G – Notification of issue, conversion or payment up of equity +securities |
27/02/2020 |
1H FY2020 Financial Results |
04/02/2020 |
Cellmid’s evolis patent to be granted in China |
29/01/2020 |
Cellmid Limited notes to the Appendix 4C |
06/01/2020 |
Key Midkine Antibody Patents granted in the US and Europe |